With a high percentage of BRCA1 associated breast cancers being classified as triple-negative, the assessment of TR expression in those patients may turn out to be attractive in terms of alternative treatment options, applicable especially for breast cancer patients carrying a BRCA1 germline mutation. The gene discussed is BRCA1; the disease is breast carcinoma.